位置:成果数据库 > 期刊 > 期刊详情页
伊马替尼停药后复发胃肠道间质瘤的临床特征与KIT/PDGFR基因突变分析
  • ISSN号:1004-0781
  • 期刊名称:《医药导报》
  • 时间:0
  • 分类:S858.28[农业科学—临床兽医学;农业科学—兽医学;农业科学—畜牧兽医] TQ463.4[化学工程—制药化工]
  • 作者机构:[1]Department of Oncology Surgery, Xuzhou Central Hospital (Affiliated Hospital of Medical College of Southeast University), Xuzhou 221009, China, [2]Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China, [3]Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030,China, [4]Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
  • 相关基金:supported by grants from the National Natural Science Foundation of China(No.81072431); the Innova-tion Foundation of Huazhong University of Science and Tech-nology(No.2010MS027)
中文摘要:

5-aminosalicylic acid(5-ASA)is drug of choice for the treatment of ulcerative colitis(UC).In this study,the efficacy of topical versus oral 5-ASA for the treatment of UC was examined as well as the action mechanism of this medication.A flexible tube was inserted into the rat cecum to establish a topical administration model of 2,4,6-trinitrobenzene sulfonic acid(TNBS)-induced UC.A total of 60rats were divided into sham operation group(receiving an enema of 0.9%saline solution instead of the TNBS solution via the tube),model group,topical 5-ASA group,oral Etiasa group(a release agent of mesalazine used as positive control)and oral 5-ASA group(n=12 each).Different treatments were administered 1 day after UC induction.The normal saline(2 mL)was instilled twice a day through the tube in the sham operation group and model group.5-ASA was given via the tube in the topical 5-ASA group(7.5 g/L,twice per day,100 mg/kg),and rats in the oral Etiasa group and oral 5-ASA group intragastrically received Etiasa(7.5 g/L,twice per day,100 mg/kg)and 5-ASA(7.5 g/L,twice per day,100mg/kg),respectively.The body weight was recorded every day.After 7 days of treatment,blood samples were drawn from the heart to harvest the sera.Colonic tissues were separated and prepared for pathological and related molecular biological examinations.The concentrations of 5-ASA were detected at different time points in the colonic tissues,feces and sera in different groups by using the high pressure liquid chromatography(HPLC).The results showed that the symptoms of acute UC,including bloody diarrhea and weight loss,were significantly improved in topical 5-ASA-treated rats.The colonic mucosal damage,both macroscopical and histological,was significantly relieved and the myeloperoxidase activity was markedly decreased in rats topically treated with 5-ASA compared with those treated with oral 5-ASA or Etiasa.The mRNA and protein expression of IL-1β,IL-6,and TNF-αwas down-regulated in the colonic tissue of rats topically treated with 5-ASA,significantly lo

英文摘要:

5-aminosalicylic acid(5-ASA) is drug of choice for the treatment of ulcerative colitis(UC). In this study, the efficacy of topical versus oral 5-ASA for the treatment of UC was examined as well as the action mechanism of this medication. A flexible tube was inserted into the rat cecum to establish a topical administration model of 2,4,6-trinitrobenzene sulfonic acid(TNBS)-induced UC. A total of 60 rats were divided into sham operation group(receiving an enema of 0.9% saline solution instead of the TNBS solution via the tube), model group, topical 5-ASA group, oral Etiasa group(a release agent of mesalazine used as positive control) and oral 5-ASA group(n=12 each). Different treatments were administered 1 day after UC induction. The normal saline(2 mL) was instilled twice a day through the tube in the sham operation group and model group. 5-ASA was given via the tube in the topical 5-ASA group(7.5 g/L, twice per day, 100 mg/kg), and rats in the oral Etiasa group and oral 5-ASA group intragastrically received Etiasa(7.5 g/L, twice per day, 100 mg/kg) and 5-ASA(7.5 g/L, twice per day, 100 mg/kg), respectively. The body weight was recorded every day. After 7 days of treatment, blood samples were drawn from the heart to harvest the sera. Colonic tissues were separated and prepared for pathological and related molecular biological examinations. The concentrations of 5-ASA were detected at different time points in the colonic tissues, feces and sera in different groups by using the high pressure liquid chromatography(HPLC). The results showed that the symptoms of acute UC, including bloody diarrhea and weight loss, were significantly improved in topical 5-ASA-treated rats. The colonic mucosal damage, both macroscopical and histological, was significantly relieved and the myeloperoxidase activity was markedly decreased in rats topically treated with 5-ASA compared with those treated with oral 5-ASA or Etiasa. The mRNA and protein expression of IL-1β, IL-6, and TNF-α was down-

同期刊论文项目
同项目期刊论文
期刊信息
  • 《医药导报》
  • 北大核心期刊(2011版)
  • 主管单位:湖北省食品药品监督管理局
  • 主办单位:中国药理学会、华中科技大学同济医学院附属同济医院
  • 主编:杜光
  • 地址:武汉市解放大道1095号
  • 邮编:430030
  • 邮箱:yydbzz@163.com
  • 电话:027-83663559 83643083 83666619
  • 国际标准刊号:ISSN:1004-0781
  • 国内统一刊号:ISSN:42-1293/R
  • 邮发代号:38-173
  • 获奖情况:
  • 2005年、2007年获湖北省优秀医学期刊奖,2010年获湖北省医学优秀精品期刊奖,2011年获湖北省医学优秀精品期刊
  • 国内外数据库收录:
  • 美国化学文摘(网络版),波兰哥白尼索引,美国乌利希期刊指南,中国中国科技核心期刊,中国北大核心期刊(2011版)
  • 被引量:33223